Navigation Links
StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
Date:1/22/2013

LONDON, January 22, 2013 /PRNewswire/ --

The medical appliances and equipment industry faced its fair share of challenges during the recession, as procedural volume in some cases was reduced due to the economic situation in the U.S. and Europe. Analysts from our services research team completed in-depth analysis on Boston Scientific Corporation (NYSE: BSX) and Medtronic Inc. (NYSE: MDT). These free reports are available at

http://www.stockcall.com/registration    

Competition also crimped margins for several companies, leading to lower sales and profits. However, with the recession in the rear view mirror, the outlook for the industry and companies such as Boston Scientific and Medtronic is positive. Now that companies have been afforded some breathing room, they are focusing their attentions on bringing new products to market and growing their international footprint. Download the free report on Scientific by signing up now at

http://www.StockCall.com/BSX012213.pdf

Both Boston Scientific and Medtronic [Free Report on MDT][1] have been looking to new products to grow their top- and bottom-lines, and both have recently been involved with paroxysmal atrial fibrillation. Atrial fibrillation affects around 15 million people globally, and can cause serious health problems such as strokes and heart failure.

In the case of Boston Scientific, the company newly announced that the first patient has been treated in its ZERO AF clinical trial. The results of the trial are anticipated to be used to back up an FDA regulatory submission for a paroxysmal atrial fibrillation indication.

Medtronic has also been busy, recently stating that the FDA has cleared the FlexCath Advance (TM) Steerable Sheath, an improvement to the Arctic Front Advance (TM) Cryoballon System. The new sheath will make it easier to reach inferior veins of the heart when delivering and positioning the cryoballoon catheter in the left atrium to treat paroxysmal atrial fibrillation.

Footer:

  1. Medtronic Inc. Technical Analysis [ http://www.StockCall.com/MedtronicInc012213.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation
2. Russian Government Starts Using Scopus for National Research Assessment
3. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
4. US Vitamin injections Posts New Research Involving B Vitamin Deficiency
5. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
6. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
7. BodyMedia Collaborates on Federal Health Research Study
8. Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
11. German Cancer Research Center Selects Contur ELN from Accelrys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... 1, 2017 Michael Penna , President ... highlights opportunities for growth in his response to the ... Equity is seeking a buyer for eMDs. Penna,s company, ... healthcare solutions Value Added Reseller and national leader in ... "As the healthcare market continues to dictate ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... Va. , Aug. 29, 2017 ivWatch, LLC, the ... peripheral IV infiltrations, announced it has been awarded an Innovative Technology ... company in the country. ... continuous monitoring device to aid in the early detection of peripheral ... The Innovative ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO of Team ... week about the value of senior executives, pointed to a quote from William ... has brought us to the present and will lead us into the future," ...
(Date:9/20/2017)... ... 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl ... published author, Jeanine Liston, a busy mother of five who used her time waiting for ... this book for over twenty years. It was a way to give some meaning ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her ... for a murderer starts revealing the skeletons in their closets. “They Sang At Her ... is now fifty-six years young and married with five children and twelve grandchildren. Before ...
(Date:9/19/2017)... ... September 19, 2017 , ... With a series of ... more than $15,000 in just a couple of weeks for those affected by ... world-class instructor seminars, organizers expect to double those initial funds with the “Submit ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola ... strategic marketing leader, Denise Flannery, to its strategic advisory and client development team. ... Denise will work with clients across different industries to develop and implement market-justified ...
Breaking Medicine News(10 mins):